Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.66 Increased by +51.47% | -0.96 Increased by +31.25% |
| Aug 8, 23 | -0.85 Increased by +55.26% | -0.86 Increased by +1.16% |
| May 9, 23 | -0.76 Increased by +72.86% | -1.08 Increased by +29.63% |
| Mar 15, 23 | -1 Increased by +44.44% | -1.05 Increased by +4.76% |
| Nov 8, 22 | -1.36 Increased by +54.67% | -1.65 Increased by +17.58% |
| Aug 12, 22 | -1.9 Increased by +40.63% | -2.8 Increased by +32.14% |
| May 10, 22 | -2.8 Increased by +3.45% | -2.57 Decreased by -8.95% |
| Mar 15, 22 | -1.8 Increased by +51.35% | -3.85 Increased by +53.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -15.29 M Decreased by -7.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by -100% | -12.21 M Increased by +12.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -12.08 M Increased by +38.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -236 K Decreased by -104.93% | -13.76 M Decreased by -28.67% | Increased by +5.83 K% Increased by +2.71 K% |
| Sep 30, 22 | 0 Decreased by N/A% | -14.29 M Increased by +13.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 236 K Increased by +N/A% | -14.02 M Increased by +21.37% | Decreased by -5.94 K% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -19.56 M Decreased by -24.16% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 4.78 M Increased by +N/A% | -10.69 M Increased by +45.41% | Decreased by -223.52% Decreased by N/A% |